Overview

A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants

Status:
Not yet recruiting

Trial end date:
2023-08-25

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effect of BMS-986196 when coadministered with combined hormonal oral contraceptives (ethinyl estradiol [EE] and norethindrone [NET]) in healthy female participants.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Estradiol
Ethinyl Estradiol
Norethindrone
Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination